➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
McKinsey
Mallinckrodt
McKesson
Johnson and Johnson

Last Updated: April 22, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IMMUNE GLOBULIN (HUMAN)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for immune globulin (human)

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000580 Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1975-11-01 To evaluate whether hepatitis B immune globulin with a high level of antibody against the hepatitis B antigen would be capable of interrupting maternal-fetal transmission of hepatitis B virus, the single most important route of hepatitis spread in the entire Third World.
NCT00000584 Transfusion-Transmitted Cytomegalovirus Prevention in Neonates Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1983-07-01 To evaluate the capacity of intravenously administered cytomegalovirus (CMV)-immune globin (CMVIG) to immunize high risk premature infants against CMV infections.
NCT00000751 A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) Completed National Institute of Allergy and Infectious Diseases (NIAID) Phase 3 1969-12-31 To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine (AZT) administered intrapartum and to the newborn, on incidence of HIV infection in infants born to HIV-infected women who received AZT during pregnancy for medical indications. Vertical transmission of HIV from mother to child may occur before, during, or after parturition (via breast-feeding). It is believed that therapy administered both during pregnancy and intrapartum may help prevent vertical transmission. Additionally, adjunctive short-term antiretroviral therapy for the newborn, following the intensive viral exposure presumed to occur at birth, may be necessary.
NCT00000751 A Phase III Randomized, Double-Blind, Controlled Study of the Use of Anti-HIV Immune Serum Globulin (HIVIG) for the Prevention of Maternal-Fetal HIV Transmission in Pregnant Women and Newborns Receiving Zidovudine (AZT) Completed Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Phase 3 1969-12-31 To evaluate the effect of anti-HIV immune serum globulin (HIVIG) versus immune globulin (IVIG) administered during pregnancy and to the newborn, in combination with zidovudine (AZT) administered intrapartum and to the newborn, on incidence of HIV infection in infants born to HIV-infected women who received AZT during pregnancy for medical indications. Vertical transmission of HIV from mother to child may occur before, during, or after parturition (via breast-feeding). It is believed that therapy administered both during pregnancy and intrapartum may help prevent vertical transmission. Additionally, adjunctive short-term antiretroviral therapy for the newborn, following the intensive viral exposure presumed to occur at birth, may be necessary.
NCT00000827 A Phase I/II Study of Hyperimmune IVIG in Slowing Progression of Disease in HIV-Infected Children Completed North American Biologicals Inc Phase 1 1969-12-31 To evaluate the safety, tolerance, pharmacokinetics, and antiviral activity of human anti-HIV immune serum globulin ( HIVIG ) at three dosage levels in HIV-infected children. Passive antibody therapy has been used with limited success in treating advanced HIV disease in adults. HIVIG is manufactured from HIV antibody-rich plasma taken from asymptomatic donors. It is hypothesized that HIVIG will decrease the viral burden of moderately advanced HIV-positive children.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for immune globulin (human)

Condition Name

Condition Name for immune globulin (human)
Intervention Trials
Leukemia 55
Lymphoma 36
Myelodysplastic Syndromes 29
Multiple Myeloma and Plasma Cell Neoplasm 21
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for immune globulin (human)
Intervention Trials
Leukemia 69
Myelodysplastic Syndromes 50
Preleukemia 50
Lymphoma 42
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for immune globulin (human)

Trials by Country

Trials by Country for immune globulin (human)
Location Trials
United States 573
Canada 40
Germany 20
China 15
France 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for immune globulin (human)
Location Trials
Texas 48
California 42
New York 40
Ohio 34
Maryland 32
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for immune globulin (human)

Clinical Trial Phase

Clinical Trial Phase for immune globulin (human)
Clinical Trial Phase Trials
Phase 4 18
Phase 3 31
Phase 2/Phase 3 11
[disabled in preview] 130
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for immune globulin (human)
Clinical Trial Phase Trials
Completed 114
Recruiting 50
Terminated 22
[disabled in preview] 38
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for immune globulin (human)

Sponsor Name

Sponsor Name for immune globulin (human)
Sponsor Trials
National Cancer Institute (NCI) 58
M.D. Anderson Cancer Center 26
National Heart, Lung, and Blood Institute (NHLBI) 18
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for immune globulin (human)
Sponsor Trials
Other 245
NIH 104
Industry 68
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Baxter
Boehringer Ingelheim
AstraZeneca
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.